Neuland Laboratories Bilan de santé
Santé financière contrôle des critères 6/6
Neuland Laboratories possède un total de capitaux propres de ₹14.0B et une dette totale de ₹941.5M, ce qui porte son ratio d'endettement à 6.7%. Son actif total et son passif total sont ₹19.4B et de ₹5.5B. L'EBIT de Neuland Laboratories est ₹3.5B ce qui fait que son ratio de couverture des intérêts -5315.1. Elle dispose de liquidités et de placements à court terme de ₹1.9B.
Informations clés
6.7%
Ratio d'endettement
₹941.46m
Dette
| Ratio de couverture des intérêts | -5315.1x |
| Argent liquide | ₹1.90b |
| Fonds propres | ₹13.95b |
| Total du passif | ₹5.49b |
| Total des actifs | ₹19.44b |
Mises à jour récentes de la santé financière
Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12
Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Analyse de la situation financière
Passif à court terme: Les actifs à court terme de NEULANDLAB ( ₹9.7B ) dépassent ses passifs à court terme ( ₹4.1B ).
Passif à long terme: Les actifs à court terme de NEULANDLAB ( ₹9.7B ) dépassent ses passifs à long terme ( ₹1.4B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: NEULANDLAB dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de NEULANDLAB a été réduit de 28.1% à 6.7% au cours des 5 dernières années.
Couverture de la dette: La dette de NEULANDLAB est bien couverte par le flux de trésorerie opérationnel ( 261% ).
Couverture des intérêts: NEULANDLAB gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.